Setmelanotide is a melanocortin-4 receptor (MC4R) agonist designed to treat hyperphagia and obesity. Rhythm is evaluating setmelanotide in a global Phase 3 trial in patients with acquired hypothalamic ...
Unlock the latest advancements in obesity treatment. Expert insights reveal groundbreaking medical breakthroughs and ...
Rhythm Pharmaceuticals (NASDAQ:RYTM – Free Report) had its target price increased by Needham & Company LLC from $64.00 to $66 ...
Charles Schwab Investment Management Inc. grew its holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) by ...
which activates the leptin receptor (LEPR) mostly expressed in the hypothalamus. Therapeutic use of leptin has been limited partly by its short half-life and its inability to cross the BBB.
Roche and Zealand reason petrelintide could deliver weight loss comparable to glucagon-like peptide 1 (GLP-1) receptor agonists but without the side effects associated with GLP-1 drugs.
Pippa flops by the Aga oven chewing on a stick. At just 12 weeks old, this Labrador retriever puppy looks cute but clueless.
Clinical Trials Arena on MSN1d
Enrolment concludes in Zealand’s Phase IIb obesity therapy trialZealand Pharma has concluded enrolment for its global, randomised Phase IIb ZUPREME-1 trial, assessing petrelintide.
BRP, identified through peptide prediction, may revolutionize weight loss treatment, offering efficacy without the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback